These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29528635)

  • 1. Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.
    Que NLS; Crowley VM; Duerfeldt AS; Zhao J; Kent CN; Blagg BSJ; Gewirth DT
    J Med Chem; 2018 Apr; 61(7):2793-2805. PubMed ID: 29528635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design.
    Immormino RM; Metzger LE; Reardon PN; Dollins DE; Blagg BS; Gewirth DT
    J Mol Biol; 2009 May; 388(5):1033-42. PubMed ID: 19361515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligand-induced conformational shift in the N-terminal domain of GRP94, an Hsp90 chaperone.
    Immormino RM; Dollins DE; Shaffer PL; Soldano KL; Walker MA; Gewirth DT
    J Biol Chem; 2004 Oct; 279(44):46162-71. PubMed ID: 15292259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of unliganded GRP94, the endoplasmic reticulum Hsp90. Basis for nucleotide-induced conformational change.
    Dollins DE; Immormino RM; Gewirth DT
    J Biol Chem; 2005 Aug; 280(34):30438-47. PubMed ID: 15951571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones.
    Dollins DE; Warren JJ; Immormino RM; Gewirth DT
    Mol Cell; 2007 Oct; 28(1):41-56. PubMed ID: 17936703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ATPase cycle of the endoplasmic chaperone Grp94.
    Frey S; Leskovar A; Reinstein J; Buchner J
    J Biol Chem; 2007 Dec; 282(49):35612-20. PubMed ID: 17925398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90.
    Huck JD; Que NLS; Immormino RM; Shrestha L; Taldone T; Chiosis G; Gewirth DT
    J Biol Chem; 2019 Nov; 294(44):16010-16019. PubMed ID: 31501246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation.
    Soldano KL; Jivan A; Nicchitta CV; Gewirth DT
    J Biol Chem; 2003 Nov; 278(48):48330-8. PubMed ID: 12970348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of hsp90 paralogs: Uncovering the role of helix 1 in Grp94-selective ligand binding.
    Que NLS; Seidler PM; Aw WJ; Chiosis G; Gewirth DT
    bioRxiv; 2024 Aug; ():. PubMed ID: 37577523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine nucleotides and the regulation of GRP94-client protein interactions.
    Rosser MF; Trotta BM; Marshall MR; Berwin B; Nicchitta CV
    Biochemistry; 2004 Jul; 43(27):8835-45. PubMed ID: 15236592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural transitions accompanying the activation of peptide binding to the endoplasmic reticulum Hsp90 chaperone GRP94.
    Wearsch PA; Voglino L; Nicchitta CV
    Biochemistry; 1998 Apr; 37(16):5709-19. PubMed ID: 9548957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Grp94 inhibitor.
    Duerfeldt AS; Peterson LB; Maynard JC; Ng CL; Eletto D; Ostrovsky O; Shinogle HE; Moore DS; Argon Y; Nicchitta CV; Blagg BS
    J Am Chem Soc; 2012 Jun; 134(23):9796-804. PubMed ID: 22642269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94. II. Ligand-mediated activation of GRP94 molecular chaperone and peptide binding activity.
    Wassenberg JJ; Reed RC; Nicchitta CV
    J Biol Chem; 2000 Jul; 275(30):22806-14. PubMed ID: 10816560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Grp94, the endoplasmic reticulum Hsp90, has a similar solution conformation to cytosolic Hsp90 in the absence of nucleotide.
    Krukenberg KA; Böttcher UM; Southworth DR; Agard DA
    Protein Sci; 2009 Sep; 18(9):1815-27. PubMed ID: 19554567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the Functional Complementation between Grp94 and Hsp90.
    Maharaj KA; Que NL; Hong F; Huck JD; Gill SK; Wu S; Li Z; Gewirth DT
    PLoS One; 2016; 11(11):e0166271. PubMed ID: 27824935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Grp on the Hsp90 mechanism.
    Richter K; Reinstein J; Buchner J
    Mol Cell; 2007 Oct; 28(2):177-9. PubMed ID: 17964255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.
    Mishra SJ; Ghosh S; Stothert AR; Dickey CA; Blagg BS
    ACS Chem Biol; 2017 Jan; 12(1):244-253. PubMed ID: 27959508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a Potent Grp94 Selective Inhibitor with Anti-Inflammatory Efficacy in a Mouse Model of Ulcerative Colitis.
    Jiang F; Guo AP; Xu JC; You QD; Xu XL
    J Med Chem; 2018 Nov; 61(21):9513-9533. PubMed ID: 30351001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94. I. Evidence for allosteric regulation of ligand binding.
    Rosser MF; Nicchitta CV
    J Biol Chem; 2000 Jul; 275(30):22798-805. PubMed ID: 10816561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of radamide analogs as Grp94 inhibitors.
    Muth A; Crowley V; Khandelwal A; Mishra S; Zhao J; Hall J; Blagg BS
    Bioorg Med Chem; 2014 Aug; 22(15):4083-98. PubMed ID: 25027801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.